WARNINGS
Myopathy/
In clinical trials, there was no excess of myopathy or rhabdomyolysis associated with ezetimibe compared with the relevant control arm (placebo or HMG-CoA reductase inhibitor alone). However, myopathy and rhabdomyolysis are known adverse reactions to HMG-CoA reductase inhibitors and other lipid-lowering drugs. In clinical trials, the
Because VYTORIN contains simvastatin, the risk of myopathy/rhabdomyolysis is increased by
Potent inhibitors of CYP3A4:
Cyclosporine, itraconazole, ketoconazole, erythromycin,clarithromycin, HIV protease inhibitors, nefazodone, or large quantities of grapefruit juice(>1 quart daily), particularly with higher doses of VYTORIN (see CLINICAL PHARMACOLOGY,Pharmacokinetics; PRECAUTIONS, Drug Interactions, CYP3A4 Interactions).
Other drugs:
Gemfibrozil, particularly with higher doses of VYTORIN (see CLINICAL PHARMACOLOGY,Pharmacokinetics; PRECAUTIONS, Drug Interactions, Interactions with lipid-lowering drugs that cancause myopathy when given alone).
Other lipid-lowering drugs (other fibrates or =1 g/day of
